Replies to post #208066 on Biotech Values

[linhdtu]

Guyer is so oily.Days before announcing disappointing P3s results, OPHT put on new hiring announcements on linkedin so as to support the pps for mgt to sell.

[DewDiligence]

OPHT gets no bounce from Strategic Review announcement:

http://finance.yahoo.com/news/ophthotech-announces-strategic-review-plan-113000406.html

No bounce is warranted insofar as there is nothing in the PR that could be construed as unexpected.

[DewDiligence]

OPTH’s third—(and final)—Fovista phase-3 fails:

https://finance.yahoo.com/news/ophthotech-announces-results-third-phase-103000016.html

The addition of 1.5mg of Fovista to an Eylea or Avastin regimen did not result in benefit as measured by the mean change in visual acuity at the 12-month time point.

The stock is -9%/PM, implying (surprisingly) that some investors still had hope for the Fovista program.